Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Long-Term Evaluation of Bone Cementoplasty in Multiple Myeloma Patients

Samer Soliman, Laurent Garderet, Kevin Premat, Julien Allard, Atika Talbi, Mehdi Drir, Mahmoud Elhorany, Nada Hamad, Sylvain Choquet, pierre Marie Chiaroni, Frederic Clarençon, Eimad Shotar

Blood (2024) 144 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2024-202194

Published: 2024

Journal Articles

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3 -ITD–mutated, relapsed or refractory AML

Jorge E. Cortes, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

Blood (2018) 132 (6): 598–607.

https://doi.org/10.1182/blood-2018-01-821629

Published: 2018

Includes: Supplemental data

Journal Articles

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Blood (2017) 130 (Supplement 1): 3850.

https://doi.org/10.1182/blood.V130.Suppl_1.3850.3850

Published: 2017

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Pierre Hirsch, MD, Myriam Labopin, Christophe Marzac, MD, Anne-Claire Mamez, MD, Ruoping Tang, Françoise Isnard, MD, Simona Lapusan, Anne Vekhoff, MD, Norbert C Gorin, MD, Jean-Pierre Marie, Mohamad Mohty, Ollivier Legrand, MD PhD

Blood (2014) 124 (21): 1033.

https://doi.org/10.1182/blood.V124.21.1033.1033

Published: 2014

Journal Articles

Gihp-Naco Prospective Registry: Characterization and Care of Major Bleeding in Patients Treated By Direct Oral Anticoagulants

Gilles Pernod, Pierre Albaladejo, Charles-Marc Samama, Pierre-Marie Sie, MD PhD, jean Luc Bosson

Blood (2014) 124 (21): 2877.

https://doi.org/10.1182/blood.V124.21.2877.2877

Published: 2014

Journal Articles

An Interactive 3D Lymphoma's Stage Calculator Assistant: A New Tool to Help Hematologists in Routine Practice

Mohamed Touati, MD, Jeremy Assenat, Jacques Monteil, MD, Philippe De Souza, MD, Magdalena Munyamahoro, Sandra Juge, Pierre-Marie Preux, MD, Arnaud Jaccard, MD, Dominique Bordessoule, MD

Blood (2014) 124 (21): 1323.

https://doi.org/10.1182/blood.V124.21.1323.1323

Published: 2014

Journal Articles

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation

Leonie I. Kroeze, Mariam G. Aslanyan, Arno van Rooij, Theresia N. Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B. Boezeman, Jean-Pierre Marie, Constantijn J. M. Halkes, Theo de Witte, Gerwin Huls, Stefan Suciu, Ron A. Wevers, Bert A. van der Reijden, Joop H. Jansen

Blood (2014) 124 (7): 1110–1118.

https://doi.org/10.1182/blood-2013-08-518514

Published: 2014

Includes: Supplemental data

Journal Articles

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

Franck E. Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Stephane Giraudier, MD, PhD, Gabriel Etienne, MD, PHD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Pascale Cony-Makhoul, MD, Yann Guillermin, MD, Mohamad Sobh, Pharm.M., Pierre Marie, CRA, Driss Kamar, Biostat, Hesham Mohamed, MD, Denis Caillot, MD, Delphine Rea, MD, PhD

Blood (2013) 122 (21): 383.

https://doi.org/10.1182/blood.V122.21.383.383

Published: 2013

Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD

Blood (2013) 122 (21): 829.

https://doi.org/10.1182/blood.V122.21.829.829

Published: 2013

Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD

Blood (2013) 122 (21): 494.

https://doi.org/10.1182/blood.V122.21.494.494

Published: 2013

Journal Articles

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Emmanuelle Kempf, Pierre Hirsch, Myriam Labopin, Christophe Marzac, MD, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, MD, Mohamad Mohty, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2013) 122 (21): 2658.

https://doi.org/10.1182/blood.V122.21.2658.2658

Published: 2013

Journal Articles

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, Theresia N Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B Boezeman, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD, PhD, Theo M. de Witte, MD, Gerwin Huls, Stefan Suciu, PhD, Ron Wevers, Bert A. van der Reijden, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1261.

https://doi.org/10.1182/blood.V122.21.1261.1261

Published: 2013

Journal Articles

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

Pierre Hirsch, Ruoping Tang, Christophe Marzac, MD, Fanny Fava, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, Ollivier Legrand, MD, PhD

Blood (2012) 120 (21): 4909.

https://doi.org/10.1182/blood.V120.21.4909.4909

Published: 2012

Journal Articles

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Catherine Boyer-Neumann, Annie Borel-Derlon, MD, PhD, Jenny Goudemand, MD, PhD, Ségolène Claeyssens, Pierre-Marie Sie, MD, PhD, Philippe Moreau, Marie-Anne Bertrand, MD, Chantal Rothschild, MD, Benoît Guillet, MD, PhD, Jeanne Yvonne Borg, Catherine Chatelanaz, Wil Stevens, Françoise Bridey, Celine Henriet

Blood (2012) 120 (21): 3375.

https://doi.org/10.1182/blood.V120.21.3375.3375

Published: 2012

Journal Articles

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

Blood (2012) 120 (21): 2804.

https://doi.org/10.1182/blood.V120.21.2804.2804

Published: 2012

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance,

Blood (2011) 118 (21): 3612.

https://doi.org/10.1182/blood.V118.21.3612.3612

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-Term Evaluation of Bone Cementoplasty in Multiple Myeloma Patients

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3 -ITD–mutated, relapsed or refractory AML

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Gihp-Naco Prospective Registry: Characterization and Care of Major Bleeding in Patients Treated By Direct Oral Anticoagulants

An Interactive 3D Lymphoma's Stage Calculator Assistant: A New Tool to Help Hematologists in Routine Practice

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only